NO20001548D0 - Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat - Google Patents

Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat

Info

Publication number
NO20001548D0
NO20001548D0 NO20001548A NO20001548A NO20001548D0 NO 20001548 D0 NO20001548 D0 NO 20001548D0 NO 20001548 A NO20001548 A NO 20001548A NO 20001548 A NO20001548 A NO 20001548A NO 20001548 D0 NO20001548 D0 NO 20001548D0
Authority
NO
Norway
Prior art keywords
renin
combined preparation
angiotensin system
endothelin antagonist
system inhibitor
Prior art date
Application number
NO20001548A
Other languages
English (en)
Other versions
NO324382B1 (no
NO20001548L (no
Inventor
Klaus Muenter
Michael Kirchengast
Horst Korioth
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19742717A external-priority patent/DE19742717A1/de
Priority claimed from DE1997143141 external-priority patent/DE19743141A1/de
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO20001548D0 publication Critical patent/NO20001548D0/no
Publication of NO20001548L publication Critical patent/NO20001548L/no
Publication of NO324382B1 publication Critical patent/NO324382B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001548A 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen. NO324382B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19742717A DE19742717A1 (de) 1997-09-26 1997-09-26 Pharmazeutische Kombinationspräparate
DE1997143141 DE19743141A1 (de) 1997-09-30 1997-09-30 Pharmazeutische Kombinationspräparate
PCT/EP1998/005773 WO1999016445A1 (de) 1997-09-26 1998-09-10 Endothelin antagonist und renin-angitensin systems hemmer als kombinationspräparate

Publications (3)

Publication Number Publication Date
NO20001548D0 true NO20001548D0 (no) 2000-03-24
NO20001548L NO20001548L (no) 2000-03-24
NO324382B1 NO324382B1 (no) 2007-10-01

Family

ID=26040370

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001548A NO324382B1 (no) 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen.

Country Status (15)

Country Link
US (1) US6329384B1 (no)
EP (1) EP1014989B1 (no)
JP (2) JP4917707B2 (no)
KR (1) KR100623121B1 (no)
CN (1) CN1187050C (no)
AT (1) ATE257706T1 (no)
AU (1) AU750755B2 (no)
BR (1) BR9812531A (no)
CA (1) CA2304712C (no)
CZ (1) CZ299741B6 (no)
DE (1) DE59810600D1 (no)
ES (1) ES2214734T3 (no)
HU (1) HU226454B1 (no)
NO (1) NO324382B1 (no)
WO (1) WO1999016445A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
JP4917707B2 (ja) * 1997-09-26 2012-04-18 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト エンドセリン拮抗剤およびレニン−アンギオテンシン系阻害剤から成る組合せ剤
WO2007098387A2 (en) * 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
WO2008073927A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
US20090076119A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ramipril
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69422742T2 (de) * 1993-03-19 2000-08-17 Merck & Co Inc Phenoxyphenylessigsäurederivate
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP0799051B1 (en) 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
NZ298853A (en) * 1995-01-27 1998-07-28 Rhone Poulenc Rorer Ltd 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
KR20000057642A (ko) * 1996-12-18 2000-09-25 스타르크, 카르크 헤테로시클릭 카르복실산 유도체, 그의 제제 및 엔도텔린 수용체길항제로서의 용도
JP4917707B2 (ja) * 1997-09-26 2012-04-18 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト エンドセリン拮抗剤およびレニン−アンギオテンシン系阻害剤から成る組合せ剤

Also Published As

Publication number Publication date
NO324382B1 (no) 2007-10-01
AU750755B2 (en) 2002-07-25
CN1187050C (zh) 2005-02-02
CA2304712C (en) 2008-04-29
KR100623121B1 (ko) 2006-09-12
EP1014989B1 (de) 2004-01-14
JP2001517704A (ja) 2001-10-09
EP1014989A1 (de) 2000-07-05
AU9539598A (en) 1999-04-23
DE59810600D1 (de) 2004-02-19
ES2214734T3 (es) 2004-09-16
KR20010030713A (ko) 2001-04-16
HU226454B1 (en) 2008-12-29
CA2304712A1 (en) 1999-04-08
HUP0004298A3 (en) 2002-06-28
CZ20001107A3 (cs) 2000-08-16
CN1271283A (zh) 2000-10-25
JP4917707B2 (ja) 2012-04-18
NO20001548L (no) 2000-03-24
JP2012046531A (ja) 2012-03-08
HUP0004298A2 (hu) 2001-11-28
BR9812531A (pt) 2000-07-25
WO1999016445A1 (de) 1999-04-08
CZ299741B6 (cs) 2008-11-05
ATE257706T1 (de) 2004-01-15
US6329384B1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
FI973360A0 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
NO975244L (no) 5-ring-heterocykluser som inhibitorer av leukosyttadhesjon og VLA-4-antagonister
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
NO942650L (no) Farmasöytisk kombinasjonspreparat
DK1498124T3 (da) Anvendelse af inhibitorer i renin-angiotensinsystemet
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DK1119359T3 (da) 2-methyl-thieno-benzodiazepinformulering
BR9809848A (pt) Composição
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
PT866870E (pt) Proteinas de fusao factor tecidual-dominio de kunitz como inibidores do factor viia
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0110902A (pt) Inibidores de mmp-9/mmp-2
ATE239479T1 (de) Endothelin antagonist und betarezeptorenblocker als kombinationspräparate
DK0910379T3 (da) Plaster til transdermal påføring af pergolid
NO972612D0 (no) Pyridazoner som endotelinreseptorantagonister
WO2002016432A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
WO2002016433A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b
HUP9900606A2 (hu) 5-HT3 Receptor antagonisták mozgászavar kezelésére
ECSP972253A (es) Composicion farmaceutica: nueva formulacion y su uso en el tratamiento y/o profilaxis de ciertos trastornos
SE9100950L (sv) Vvs-armatur foer tvaettstaell

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MM1K Lapsed by not paying the annual fees